Tandem repeat expansion disorders Flashcards

You may prefer our related Brainscape-certified flashcards:
1
Q

Outline the two main types of repetitive DNA sequences and their subtypes.

A

Tandem repeats

  • Satellite DNA - 5-171bp, heterochromatin
  • Minisatellites - 6-64bp, telomeres
  • Microsatellites - 1-6bp, euchromatin

Interspersed repeats

  • Alu family - 280bp, giemsa +ve, euchromatin
  • Kpn (L1) family - 1300bp, giemsa -ve, euchromatin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Describe the 3 types of repeat expansions, and in each case state the effect on transcription and translation.

A
  • Modest expansions within transcribed & translated regions - contribute to final protein
  • Expansions in UTR - transcribed into RNA but not translated into protein
  • Large scale expansions within untranscribed regions - do not appear in RNA/final protein
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Describe the 4 types of DNA replication errors which could cause microsatellite expansion.

A
  1. Imperfect Okazaki fragment ligation
  2. Polymerase slipping
  3. Fork reversals
  4. Template switching
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Outline the genetic features and mode of inheritance of Huntington’s Disease.

A
  • Mutated HTT gene = IT15
    • Chromosome 4p16.3
    • Encodes Huntingtin
    • Expansion of trinucleotide CAG repeat in exon 1
  • Autosomal dominant
  • Anticipation but CAG repeat size does not equal severity
  • Longer repeat length associated with earlier onset but still variability
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Describe the neuropathology and clinical features of Huntington’s Disease.

A
  • Loss of GABAergic and cholinergic neurons in striatum (caudate nucleus and putamen) and globus pallidus
  • Chorea - twitching, uncontrolled movements, spasms - earliest motor feature
  • Bradykinesia and incoordination - disabling
  • Attencion deficit
  • Spatial disorder
  • Memory disorder
  • Disorganised speech
  • Changes in personality and emotion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Describe the relationship between (CAG)n and Huntington’s phenotype.

A
  • CAG repeats >39 = Huntington’s
  • 36-39 repeats = may or may not have disease
  • 27-35 repeats = normal but can expand
  • 11-26 repeats = normal range
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Explain the influence of de novo mutations on Hungtington’s.

A
  • High de novo mutation rate
  • 24% = no family history
  • >10% of repeats in 27-35 range expand into disease range in each generation - late onset cases under ascertained or misdiagnosed
  • Somatic expansions - unknown influence on disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Outline the normal functions of huntingtin protein.

A
  • Appears crucial for embryonic development and neurogenesis
  • Loss of huntingtin function does not lead to HD
  • Lethal in knockout mice embroys
  • Expressed throughout brain
  • Located in pre- and post-synaptic regions of axons and dendrites
  • Mainly cytoplasmic but can be nuclear
  • Associates with microtubules, vesicles and organelles
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Explain the key features of Huntington’s Disease pathogenesis, with regard to HTT.

A
  • Mutant HTT forms abnormal conformations
  • Systems for handling abnormal proteins imapired in HD
  • Cellular metabolic pathways impaired in HD
  • HTT truncated > toxic N-terminal fragments
  • Post-translational modifications of HTT influence toxicity
  • Nuclear translocation of mutant HTT enhances toxicity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Describe the 3 main pathogenic pathways thought to be involved in Huntington’s Disease.

A

Polyglutamine toxic fragment

  • Huntingtin cleaved by caspase-3 and polyQ fragment enters nucleus
  • Fragment aggregates and interferes with other transcription factors

Axonal transport

  • PolyQ expansion interferes with the interaction of Huntingtin associated protein HAP1 and p150 - a component of the dynein motor complex
  • This results in reduced axonal transport

Mitochondrial malfunction

  • PolyQ fragment may cause mitochondrial Ca2+ defects
  • Expanded CAGs cause reduced mitochondrial ATP output
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Outline the function of brain-derived neurotrophic factor (BDNF) and explain how this is thought to be affected in Huntington’s Disease.

A
  • BDNF promotes growth, maturation and differentiation of neurons
  • Active at synapses - helps to regulate synaptic plasticity
  • Mutant HTT interferes with correct function of BDNF
  • PolyQ fragment may interfere with BDNF transcription
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Outline the clinical features of myotonic dystrophy (dystrophia myotonica, DM). What is the mode of inheritance?

A
  • Subset of inherited muscular dystrophies
  • Heterogeneous
  • Affects children and adults
  • Multisystem disease
  • Core features = myotonia, muscular dystrophy, cardiac conduction defects, cataracts, endocrine disorders
  • Autosomal dominant
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Describe the main clinical manifestations of mytotonic dystrophy, including facial features.

A
  • Myotonia and progressive myopathy
  • Cardiac conduction defects, arrhythmias, cardiomyopathy
  • Insulin resistance, glucose intolerance
  • Testicular atrophy
  • Cranial hyperostosis myotonia (irritability and prolonged contraction of muscles)
  • Facial features - ‘hatchet face’, frontal balding, temporal wasting, drooping eyelids (ptosis), drooping mouth
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Name the 4 clinical groups of DM1.

A
  1. Congenital - 100% from mother
  2. Childhood onset
  3. Adult onset “classic DM1”
  4. Late-onset/asymptomatic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe the tandem repeat expansion responsible for DM type 1. Explain the clinical significance of the number of repeats.

A
  • CTG trinucleotide repeat in 3’ UTR of of DMPK (DM protein kinase) gene
  • Normal (CTG)n = 5-37
  • “Premutation” asymptomatic n = 38-49
  • DM1 phenotype n = 50-4000
  • Correlation between repeat number and severity/age of onset
  • Highest number of repeats in congenital form
  • Females with >500 copies preferentially transmit massive expansions
  • Males with >500 copies preferentially transmit contractions
  • Anticipation, somatic mosaicism
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Outline the histopathological changes seen in DM type 1. What features are revealed by muscle biopsy?

A
  • Early - myopathic changes, variable fibre size and internalised nuclei
  • Late - numerous internalised nuclei, often in longitudinal chains
  • Muscle biopsy reveals:
    • Pyknotic nuclear clumps
    • Abnormal muscle fibre types
    • Predominantly type 1 fibre atrophy
17
Q

Outline the proposed disease mechanisms in DM type 1 and the supporting evidence.

A
  1. Haploinsufficiency of DMPK - expansion at 3’ end may alter expression levels and protein amount. However, DMPK knockout mice do not have DM and no DMPK mutations are known to cause DM.
  2. Haploinsufficiency of nearby gene - CTG expansion may affect SIX5 promoter, altering chromatin structure and potentially affecting expression of multiple genes. However, studies have not found expansion to alter transcript levels of any genes.
  3. Nuclear RNA retention - ‘Gain of function toxic RNA’ mechanism acting in nucleus:
    • CUG repeats form double-stranded hairpin structures, causing nuclear trapping.
    • Expanded RNA accumulates in nucleus and sequesters splicing regulators, disrupting normal splicing of many genes > multisystem defects.
    • Disruption of CLC-1 expression = myotonia.
    • Disruption of IR expression = insulin resistance.
    • Disruption of TNNT3 (cardiac troponin T) = cardiac problems.
18
Q
A
19
Q

Outline the clinical features of DM type 2 and the differences with DM1.

A
  • Similar myotonia, weakness, cataracts, frontal balding, diabetes
  • Pain and sleep disorders are common
  • Age of onset 8-60 years
  • No congenital form
  • Prognosis more favourable than DM1 - cardiac involvement less common
    *
20
Q

Describe the genetic mechanism and pathology of DM type 2.

A
  • CNBP gene (zinc finger binding protein), 3q21.3
  • Huge expansion of (CCTG)n in intron 1
  • Healthy n < 24
  • DM2 n = 75-11,000, avg ~ 5000
  • Size does not correlate with severity/age of onset
21
Q

Outline the pathological differences and similarities between DM1 and DM2.

A
  • DMPK vs CNBP gene mutation
  • CTG vs CCTG repeat expansion
  • May be congenital vs no congenital form
  • Rough correlation of repeat size and onset vs no correlation
  • Distal>proximal weakness vs proximal>distal weakness
  • Histopathology with type 1 fibre atrophy vs type 2 fibre atrophy
  • Both toxic RNA diseases